Ares Bioscience

Executive Summary

Ares Bioscience, founded in 2018 and headquartered in San Diego, is a private contract research organization (CRO) specializing in infectious disease and antibody therapeutics. The company provides tailored in vitro and in vivo solutions, including cell line engineering, assay development, and pharmacology services, leveraging its acronym A.C.R.E.S. (Advanced Contract Researchers). By focusing on accelerating drug discovery for biopharmaceutical clients, Ares targets a growing demand for outsourced R&D in infectious disease and antibody development, particularly relevant in the post-pandemic landscape. As a small, specialized CRO, it competes with larger players by offering customized, high-touch services that appeal to biotech firms seeking flexibility and expertise.

Upcoming Catalysts (preview)

• TBDNew client contract for COVID-19 or long COVID antibody program40% success
• Q3 2026Expansion of in vivo pharmacology services to include immuno-oncology models60% success
• TBDApproval of a client's antibody therapy developed using Ares' platform20% success